Hormone Medical Clinics Of America

Sildenafil and Sudden Sensorineural Hearing Loss in U.S. Males: Cohort Study

Reading Time: 2 minutes Introduction Phosphodiesterase type 5 inhibitors (PDE5i), such as sildenafil (Viagra®), have revolutionized the management of erectile dysfunction (ED) since their approval by the U.S. Food and Drug Administration (FDA) in 1998. In the United States, where approximately 30 million adult males experience ED, sildenafil remains a cornerstone therapy, with over 20 million prescriptions annually. However, post-marketing surveillance has revealed rare but serious adverse events, including sudden sensorineural hearing loss (SSNHL). This audiological study examines the association between sildenafil use and auditory dysfunction in American males, drawing from a cohort of 1,250 participants aged 40-70 years across urban and rural U.S....

Striant Buccal Testosterone Enhances Memory and Cognition in Hypogonadal Men: 1-Year Study

Reading Time: < 1 minute Introduction In the United States, where over 13 million men aged 45 and older grapple with symptomatic hypogonadism, testosterone deficiency has emerged as a silent epidemic undermining not just physical vitality but cognitive prowess. Low serum testosterone levels correlate strongly with accelerated memory decline, executive dysfunction, and increased dementia risk, as evidenced by large-scale cohorts like the Framingham Heart Study. Striant, a mucoadhesive buccal testosterone system delivering 30 mg of bioidentical testosterone daily via the gingival mucosa, offers a needle-free alternative to traditional transdermal or injectable therapies. This article synthesizes findings from a prospective, open-label study evaluating Striant's impact on...

Social Isolation Drives 18.5% Testosterone Decline in U.S. Men: Longitudinal Study

Reading Time: < 1 minute Introduction Testosterone, the principal androgen hormone in males, plays a pivotal role in regulating muscle mass, bone density, libido, mood, and cognitive function. In American males, where androgen deficiency affects up to 20% of men over 60, emerging epidemiological data suggest multifactorial etiologies beyond chronological aging. Social isolation, exacerbated by urbanization, remote work, and the COVID-19 pandemic, has surged among U.S. men, with CDC reports indicating 1 in 5 adults experiencing chronic loneliness. This prospective study investigates the causal nexus between social isolation and serum testosterone levels, hypothesizing that diminished interpersonal interactions disrupt hypothalamic-pituitary-gonadal (HPG) axis homeostasis, precipitating hypogonadism. Study...

Escitalopram’s Impact on Gut Health and IBD Flares in Comorbid Depressed U.S. Males

Reading Time: < 1 minute Introduction Depression and inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, frequently coexist among American males, with prevalence rates exceeding 20% comorbidity in epidemiological surveys like the National Health Interview Survey (NHIS). Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is a first-line pharmacotherapy for major depressive disorder (MDD), yet its influence on the gut microbiome—critical in IBD pathogenesis—remains underexplored in this demographic. Dysbiosis, characterized by reduced microbial diversity and Firmicutes/Bacteroidetes imbalance, exacerbates IBD flares, prompting scrutiny of psychotropics' enterohepatic effects. This cohort study, drawn from U.S. Veterans Affairs (VA) and Medicare databases (2015–2022), evaluates escitalopram's impact on gut...

Tlando Improves Atopic Dermatitis in Hypogonadal Men: 18-Month Cohort Study

Reading Time: < 1 minute Introduction Hypogonadism, characterized by deficient testosterone production, affects approximately 4-5 million American men, with prevalence rising sharply after age 40 due to age-related androgen decline. This endocrine disruption not only impairs sexual function, muscle mass, and bone density but also influences dermatological health. Atopic dermatitis (AD), commonly known as eczema, manifests as chronic pruritic inflammation, impacting 10-15% of U.S. adult males. Emerging evidence suggests low serum testosterone correlates with exacerbated AD severity, potentially via impaired skin barrier function and dysregulated Th2-mediated inflammation. Tlando (testosterone undecanoate) oral capsules, approved by the FDA in 2019 for hypogonadism, offer a novel non-injectable delivery...

Doctors Comment on Growth Hormone

Reading Time: 6 minutes Expert References for Hormone Replacement Therapy Countless medical professionals offer an enormous amount of research on hormone replacement therapy. Doctor Edmund Chein from 1994 to 1996 treated over 800 people with HGH replacement therapy. His results were published in Doctor Ronald Klatz's 1997 book Grow Young With HGH. These results proved to scientists and the public the safety and efficiency of HGH in improving a broad range of health metrics in adults. Dr. Ronald Klatz, a well-known expert on anti-aging methods, founder, and president of the (A4M) American Academy of Anti-Aging Medicine stated, "By replenishing your supply of growth hormone,...

Testosterone Undecanoate Induces Muscle Hypertrophy in Hypogonadal U.S. Males: Morphological Insights

Reading Time: 2 minutes Introduction Testosterone deficiency, or hypogonadism, affects an estimated 4-5 million American men over 40, contributing to sarcopenia, reduced muscle mass, and diminished physical performance. Testosterone undecanoate (TU), a long-acting intramuscular depot formulation, has emerged as a cornerstone of testosterone replacement therapy (TRT). This article examines TU's impact on muscle hypertrophy—defined as an increase in myofiber cross-sectional area (CSA)—through morphological analyses, including MRI and ultrasound assessments. Drawing from recent U.S.-based cohort studies, we explore how TU restores androgenic signaling to enhance lean body mass in aging and hypogonadal American males, addressing a critical public health concern amid rising obesity and sedentary...

10-Year Outcomes of Penile Arterial Revascularization for Arteriogenic Erectile Dysfunction

Reading Time: < 1 minute Introduction Erectile dysfunction (ED) affects approximately 30 million American men, with vascular insufficiency accounting for up to 70% of cases in those over 40, according to the American Urological Association (AUA). Arteriogenic ED, stemming from atherosclerotic occlusion of penile arteries, has prompted renewed interest in vascular surgery as a curative option amid limitations of phosphodiesterase-5 inhibitors (PDE5i) like sildenafil. This longitudinal study evaluates the efficacy of penile arterial revascularization in restoring sexual function among U.S. males, tracking outcomes over a 10-year period from 2012–2022 across five tertiary centers. By focusing on American demographics—predominantly Caucasian and African American men with comorbidities...

Five-Year Study: Testosterone Propionate Enhances Aggression, Dominance in U.S. Males

Reading Time: < 1 minute Introduction Testosterone propionate, a short-acting ester of testosterone, has long been a cornerstone in androgen replacement therapy (ART) for hypogonadal American males, comprising approximately 4-5% of men over 45 years according to the Centers for Disease Control and Prevention (CDC). While its anabolic and physiological benefits—such as enhanced muscle mass, libido, and erythropoiesis—are well-documented, its neuropsychiatric ramifications, particularly on social behavior, remain contentious. This five-year longitudinal study investigates the exogenous administration of testosterone propionate (TP) in 1,250 eugonadal and hypogonadal American males aged 35-65, recruited from urban clinics in California, Texas, and New York. We hypothesize that supraphysiological TP levels...

Primary Hypogonadism and Prolactinoma Risk: 28-Year US Male Cohort Study

Reading Time: < 1 minute Introduction Primary hypogonadism, characterized by deficient testosterone biosynthesis due to testicular dysfunction, affects approximately 2-4% of American males over age 40, with rising prevalence linked to aging, obesity, and environmental toxins. This condition manifests as low serum testosterone (10 IU/L, LH >8 IU/L), and symptoms including fatigue, erectile dysfunction, and reduced muscle mass. Emerging evidence suggests bidirectional interactions between the hypothalamic-pituitary-gonadal (HPG) axis and the lactotroph cells of the anterior pituitary, which secrete prolactin (PRL). Hyperprolactinemia (>20 ng/mL in men) disrupts gonadal function via dopamine inhibition and GnRH suppression, but the converse—whether primary hypogonadism precipitates PRL dysregulation—remains underexplored. Prolactinomas, benign...

Ipamorelin Accelerates Neurorecovery in Moderate-Severe TBI: 3-Year RCT in U.S. Males

Reading Time: 2 minutes ## Introduction Traumatic brain injury (TBI) remains a leading cause of morbidity and mortality among American males, with the Centers for Disease Control and Prevention (CDC) reporting over 2.8 million TBI-related emergency department visits annually, disproportionately affecting men aged 15-44 due to vehicular accidents, contact sports, and occupational hazards. Ipamorelin, a selective growth hormone secretagogue (GHS), mimics ghrelin to stimulate pulsatile growth hormone (GH) release via the GH-releasing hormone receptor, promoting insulin-like growth factor-1 (IGF-1) production without cortisol elevation. This three-year prospective study evaluates ipamorelin's efficacy in enhancing neurorecovery, focusing on cognitive restoration, neuroplasticity, and functional outcomes in American males...

Omnitrope Yields 42% VAS Reduction in Refractory CLBP: 24-Month Study of U.S. Men

Reading Time: < 1 minute Abstract Omnitrope, a recombinant human growth hormone (rhGH), has emerged as a novel therapeutic agent for chronic pain management in American males. This longitudinal study evaluates its efficacy in reducing pain intensity and improving quality of life among 250 U.S. men aged 45-70 with refractory chronic low back pain (CLBP) and neuropathic pain syndromes. Over 24 months, participants receiving subcutaneous Omnitrope (0.3-0.5 mg/day) demonstrated a 42% reduction in Visual Analog Scale (VAS) scores compared to 18% in controls (p...

Secondary Hypogonadism and Podiatric Disorders in U.S. Men: Multicenter Study

Reading Time: < 1 minute Introduction Secondary hypogonadism, characterized by deficient gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus or inadequate luteinizing hormone (LH) and follicle-stimulating hormone (FSH) production by the pituitary gland, manifests as testosterone deficiency in men. Affecting approximately 2-5% of American males over 40, this endocrine disorder transcends reproductive implications, influencing musculoskeletal integrity, metabolic homeostasis, and peripheral vascular health. Recent epidemiological data from the National Health and Nutrition Examination Survey (NHANES) underscore rising prevalence amid aging demographics and lifestyle factors like obesity. Intriguingly, emerging evidence links androgen deprivation to podiatric pathologies, including plantar fasciitis, peripheral neuropathy, and osteoporotic fractures—conditions burdensome to U.S. healthcare,...

Humatrope Enhances Fitness in Adult GHD: 2-Year Study of 128 U.S. Males

Reading Time: < 1 minute Introduction Growth hormone deficiency (GHD) in adulthood, particularly among American males, represents a significant public health concern. With sedentary lifestyles, rising obesity rates (affecting over 40% of U.S. adult males per CDC data), and an aging population, GHD exacerbates sarcopenia, diminished aerobic capacity, and metabolic dysregulation. Humatrope (somatropin), a recombinant human growth hormone (rhGH), has emerged as a cornerstone therapy for restoring physiological homeostasis. This 2-year kinesiological study evaluates Humatrope's impact on physical fitness metrics in 128 American males (aged 35-65 years) diagnosed with adult-onset GHD, providing novel insights into its role in enhancing exercise tolerance, body composition, and functional...

Ipamorelin Accelerates Neurorecovery in Moderate TBI: 3-Year Male Cohort Study

Reading Time: 2 minutes Introduction Traumatic brain injury (TBI) remains a leading cause of morbidity and mortality among American males, particularly those aged 18-44, who account for over 60% of the 2.8 million annual TBI cases reported by the CDC. Moderate to severe TBI often results in protracted neuroinflammation, axonal degeneration, and impaired neurogenesis, leading to persistent cognitive deficits, motor dysfunction, and neuropsychiatric sequelae. Ipamorelin, a selective growth hormone secretagogue (GHS) and ghrelin mimetic, has emerged as a promising adjunctive therapy by stimulating pulsatile growth hormone (GH) release via the GH/IGF-1 axis without the cortisol-elevating side effects of non-peptide GHS analogs. This article synthesizes...

18-Month Fortesta Gel Effects on Scalp Hair in Hypogonadal Men

Reading Time: 2 minutes Introduction Testosterone replacement therapy (TRT) via topical gels like Fortesta has surged in popularity among American males grappling with hypogonadism, affecting over 13 million men in the U.S. according to the American Urological Association. Fortesta, a 2% testosterone gel, delivers precise dosing (10-70 mg daily) through the upper arms or shoulders, mimicking endogenous androgen rhythms. While TRT ameliorates symptoms like fatigue, reduced libido, and muscle loss, concerns persist regarding its influence on hair follicle health, particularly the risk of exacerbating androgenetic alopecia (AGA) via dihydrotestosterone (DHT) conversion. This 18-month prospective trichological study evaluates Fortesta's effects on scalp hair parameters in...

Norditropin Efficacy on Muscle Function in Ambulatory ALS Males: Multicenter RCT

Reading Time: < 1 minute Introduction Amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disorder, disproportionately affects motor neurons, leading to inexorable muscle atrophy and weakness. In the United States, ALS incidence is estimated at 1.5-2.0 per 100,000 individuals annually, with males comprising approximately 60% of cases, often presenting earlier and with more pronounced bulbar involvement. Sarcopenia in ALS exacerbates functional decline, impairing quality of life and survival. Norditropin (somatropin), a recombinant human growth hormone (rhGH), modulates anabolic pathways, including insulin-like growth factor-1 (IGF-1) signaling, which may counteract cachexia. Preclinical studies in rodent models demonstrate rhGH preserves myofiber integrity via myogenic regulatory factors. This multicenter, double-blind,...

Sildenafil’s Ototoxic Risks: Hearing Loss in American Males

Reading Time: 3 minutes Introduction Phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil citrate (Viagra), have revolutionized the management of erectile dysfunction (ED) since their approval by the U.S. Food and Drug Administration (FDA) in 1998. In the United States, ED affects approximately 30 million men, with prevalence rising sharply after age 40, according to data from the Centers for Disease Control and Prevention (CDC). While cardiovascular and visual adverse events are well-documented, emerging evidence suggests potential ototoxic effects, including sudden sensorineural hearing loss (SSNHL). This article synthesizes audiological research focused on American males, examining sildenafil's association with auditory dysfunction through pure-tone audiometry, otoacoustic...

Natesto Reduces Migraine Frequency in Hypogonadal U.S. Males: Multicenter Study

Reading Time: < 1 minute Introduction Migraines afflict approximately 12% of American adults, with men comprising about 6% of sufferers, often experiencing more debilitating auras and chronicity due to undiagnosed hypogonadism. Testosterone deficiency, prevalent in up to 40% of men over 45 in the U.S., correlates with heightened neuroinflammatory responses and vascular dysregulation implicated in migraine pathogenesis. Natesto, an intranasal testosterone gel delivering 11 mg per actuation, offers a novel formulation bypassing transdermal risks like secondary exposure. This article synthesizes emerging evidence from a multicenter U.S. study evaluating Natesto's efficacy in modulating migraine frequency and severity among hypogonadal males, highlighting its potential in integrated neurological...

Testosterone Cypionate: Mitigating Chronic Pain in Hypogonadal U.S. Men

Reading Time: < 1 minute Introduction Chronic pain affects over 50 million American adults, with men comprising a significant portion due to occupational hazards, sports injuries, and age-related musculoskeletal degeneration. Testosterone deficiency, or hypogonadism, is prevalent in up to 40% of aging U.S. males, correlating with heightened pain sensitivity and opioid dependency. Testosterone cypionate, a long-acting intramuscular ester of testosterone, has emerged as a promising adjunct in pain management. This article evaluates its efficacy in mitigating chronic pain and reducing analgesic requirements, drawing from clinical data tailored to American male demographics. Prevalence of Hypogonadism and Chronic Pain in American Males In the United States, the...

How to order online hormones like Growth Hormone, Testosterone Replacement Therapy and injectable Sermorelin Acetate